MY208153A - Solid dispersion and preparation method therefor - Google Patents
Solid dispersion and preparation method thereforInfo
- Publication number
- MY208153A MY208153A MYPI2021007073A MYPI2021007073A MY208153A MY 208153 A MY208153 A MY 208153A MY PI2021007073 A MYPI2021007073 A MY PI2021007073A MY PI2021007073 A MYPI2021007073 A MY PI2021007073A MY 208153 A MY208153 A MY 208153A
- Authority
- MY
- Malaysia
- Prior art keywords
- solid dispersion
- preparation
- method therefor
- difluorophenoxy
- ynyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Colloid Chemistry (AREA)
Abstract
Solid dispersion and a preparation method therefor. In a specific embodiment, the solid dispersion contains an active ingredient (R)-4-amino-1-(1-(but-2-ynyl)pyrrolidin- 3-yl) )-3-(4-(2,6-difluorophenoxy)phenyl) 1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7- one or a salt thereof, and a carrier material, and the pH value is adjusted; employing a method that adds an appropriate amount of acid 10 effectively inhibits an emulsification phenomenon in a reverse solvent process, thereby obtaining solid dispersion having a moderate particle size and uniform content.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910468254 | 2019-05-31 | ||
| PCT/CN2020/093206 WO2020239065A1 (en) | 2019-05-31 | 2020-05-29 | Solid dispersion and preparation method therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY208153A true MY208153A (en) | 2025-04-18 |
Family
ID=73553512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021007073A MY208153A (en) | 2019-05-31 | 2020-05-29 | Solid dispersion and preparation method therefor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220233449A1 (en) |
| EP (1) | EP3977997A4 (en) |
| JP (1) | JP7603618B2 (en) |
| KR (1) | KR20220016116A (en) |
| CN (1) | CN113825511B (en) |
| AU (1) | AU2020282470A1 (en) |
| BR (1) | BR112021023691A2 (en) |
| CA (1) | CA3141921A1 (en) |
| MX (1) | MX2021014402A (en) |
| MY (1) | MY208153A (en) |
| TW (1) | TW202100527A (en) |
| WO (1) | WO2020239065A1 (en) |
| ZA (1) | ZA202110055B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2023182332A1 (en) * | 2022-03-22 | 2023-09-28 | ||
| KR20240133859A (en) | 2023-02-28 | 2024-09-05 | 한국표준과학연구원 | Screening method of drugs for preventing or treating SARS-CoV-2 using lung oagnoid |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0808840A2 (en) * | 2007-03-12 | 2014-09-02 | Reddy S Laborartories Ltd Dr | IMATINIB MESILATE |
| CA2738573C (en) | 2009-04-03 | 2013-02-19 | F. Hoffmann-La Roche Ag | Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof |
| NZ708272A (en) | 2013-01-22 | 2020-07-31 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
| KR102073797B1 (en) | 2014-07-07 | 2020-02-05 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Aminopyridazinone compounds as protein kinase inhibitors |
| WO2016082705A1 (en) * | 2014-11-27 | 2016-06-02 | 华东理工大学 | Insoluble active ingredient particulate, particulate preparation and preparation method therefor |
| WO2016088074A1 (en) * | 2014-12-03 | 2016-06-09 | Dr. Reddy’S Laboratories Limited | Process for the preparation of amorphous ibrutinib |
| CN106924262A (en) * | 2015-12-31 | 2017-07-07 | 常州方楠医药技术有限公司 | A kind of solid dispersions of unformed tropsch imatinib citrate and pharmaceutic adjuvant and preparation method thereof |
| ES2875384T3 (en) * | 2016-01-05 | 2021-11-10 | Jiangsu Hengrui Medicine Co | Crystal form of BTK kinase inhibitor and method of its preparation |
| IN201621020494A (en) * | 2016-06-15 | 2017-12-22 | ||
| KR102697985B1 (en) | 2017-07-04 | 2024-08-23 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Pharmaceutical composition and method for preparing same |
-
2020
- 2020-05-29 TW TW109118103A patent/TW202100527A/en unknown
- 2020-05-29 KR KR1020217041733A patent/KR20220016116A/en not_active Ceased
- 2020-05-29 BR BR112021023691A patent/BR112021023691A2/en unknown
- 2020-05-29 WO PCT/CN2020/093206 patent/WO2020239065A1/en not_active Ceased
- 2020-05-29 AU AU2020282470A patent/AU2020282470A1/en not_active Abandoned
- 2020-05-29 CN CN202080036373.8A patent/CN113825511B/en active Active
- 2020-05-29 JP JP2021570912A patent/JP7603618B2/en active Active
- 2020-05-29 US US17/615,152 patent/US20220233449A1/en not_active Abandoned
- 2020-05-29 MY MYPI2021007073A patent/MY208153A/en unknown
- 2020-05-29 MX MX2021014402A patent/MX2021014402A/en unknown
- 2020-05-29 EP EP20812881.9A patent/EP3977997A4/en not_active Withdrawn
- 2020-05-29 CA CA3141921A patent/CA3141921A1/en active Pending
-
2021
- 2021-12-06 ZA ZA2021/10055A patent/ZA202110055B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021023691A2 (en) | 2022-04-12 |
| WO2020239065A1 (en) | 2020-12-03 |
| JP2022534610A (en) | 2022-08-02 |
| KR20220016116A (en) | 2022-02-08 |
| MX2021014402A (en) | 2022-02-14 |
| JP7603618B2 (en) | 2024-12-20 |
| EP3977997A4 (en) | 2022-07-27 |
| US20220233449A1 (en) | 2022-07-28 |
| TW202100527A (en) | 2021-01-01 |
| AU2020282470A1 (en) | 2022-01-27 |
| CN113825511B (en) | 2024-10-22 |
| EP3977997A1 (en) | 2022-04-06 |
| CN113825511A (en) | 2021-12-21 |
| CA3141921A1 (en) | 2020-12-03 |
| ZA202110055B (en) | 2023-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021062281A3 (en) | Multi-targeting effector cells and use thereof | |
| WO2020053365A3 (en) | Pesticidally active azole-amide compounds | |
| MX358592B (en) | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents. | |
| MY203853A (en) | Crystalline salts of a b-raf kinase inhibitor | |
| DK1303184T3 (en) | Preservative and storage agent for biological materials | |
| AU2008266182A8 (en) | Metabolites of the janus kinase inhibitor (r)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3- cyclopentylpropanenitrile | |
| ATE289902T1 (en) | AZOLE/AMINE OXIDE WOOD PRESERVATIVES AND FUNGICIDES | |
| PH12020550143A1 (en) | Salts of pyrrolotriazine derivatives useful as tam inhibitors | |
| EP4520398A3 (en) | Treatment of prostate cancer | |
| PT3724191T (en) | 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer | |
| EP4282409A3 (en) | Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen | |
| WO2023192630A3 (en) | Angiotensinogen-modulating compositions and methods of use thereof | |
| HK1248977A2 (en) | Method for treating hair, kit, and use of the kit | |
| DK1333812T3 (en) | Microgranules based on active substance and process for preparing the same | |
| WO2007018564A3 (en) | Enhancement of b cell proliferation by il-15 | |
| MX2021014402A (en) | DISPERSION OF SOLIDS AND METHOD OF PREPARATION OF THE SAME. | |
| MX2018015388A (en) | Compositions for biological systems and methods for preparing and using the same. | |
| WO2022218891A3 (en) | Rna compositions comprising a buffer substance and methods for preparing, storing and using the same | |
| MX2020010755A (en) | Process for treating hair. | |
| MX2019010271A (en) | Applicator system. | |
| SI1186292T1 (en) | Dry carotinoid powder with a mulit-core structure | |
| WO2024220930A8 (en) | Mapt-modulating compositions and methods of use thereof | |
| EP4335515A3 (en) | Crystal forms of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)- 2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1 -yl]acetamide | |
| AU6076500A (en) | Hypoestoxides, derivatives and agonists thereof for use as antiparasitic agents | |
| MY199479A (en) | Pharmaceutical composition and method for preparing same |